1. Home
  2. GPCR vs RCUS Comparison

GPCR vs RCUS Comparison

Compare GPCR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

N/A

Current Price

$38.79

Market Cap

3.8B

Sector

N/A

ML Signal

N/A

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

N/A

Current Price

$24.67

Market Cap

3.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GPCR
RCUS
Founded
2016
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.8B
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
GPCR
RCUS
Price
$38.79
$24.67
Analyst Decision
Strong Buy
Buy
Analyst Count
12
10
Target Price
$103.17
$31.90
AVG Volume (30 Days)
755.9K
1.1M
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$247,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$45.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.04
$11.30
52 Week High
$94.90
$31.74

Technical Indicators

Market Signals
Indicator
GPCR
RCUS
Relative Strength Index (RSI) 27.86 33.18
Support Level $36.11 $25.94
Resistance Level $41.50 $26.43
Average True Range (ATR) 2.45 1.22
MACD -1.11 -0.38
Stochastic Oscillator 2.07 0.00

Price Performance

Historical Comparison
GPCR
RCUS

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: